

INTERIM REPORT

JANUARY-JUNE 2022

SECOND QUARTER, APRIL-JUNE 2022

- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to MSEK -8.7 (-6.5)
- Net loss amounted to MSEK -8.7 (-7.9)
- Net cash flow amounted to MSEK +3.8 (-6.2)
- EPS before and after dilution amounted to SEK -0.37 (-0.68)

JANUARY-JUNE 2022

- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to -16.0 (-7.5)
- Net loss amounted to MSEK -16.0 (-9.3)
- Net cash flow amounted to MSEK -1.7 (+3.3)
- EPS before and after dilution amounted to SEK -0.73 (-0.80)

“There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches.”

FINANCIAL OVERVIEW

Amounts in MSEK	Apr-Jun		Jan-Jun	
	2022	2021	2022	2021
Net sales	-	0.1	-	0.1
Operating loss	-8.7	-6.5	-16.0	-7.5
Profit/Loss for the period	-8.7	-7.9	-16.0	-9.3
Net cashflow	3.8	-6.2	-1.7	3.3
Equity ratio	0.8	0.9	0.8	0.9
Total assets	22.6	34.2	22.6	34.2
Cash and cash equivalents	22.6	34.2	22.6	34.2
EPS before and after dilution, SEK	-0.4	-0.7	-0.7	-0.8
Definitions at the end of the report				

COMMENTS BY THE CEO

We have made good progress in the second quarter on both our main projects through hard and dedicated work in-house and with external partners to meet our tight deadlines.

A key milestone was the premiere in June of **Amp01**, our consumer product with the next generation of nicotine pouches, at the world's largest nicotine forum, Global Forum on Nicotine (GFN), in Warsaw. We presented the products under our new and own brand **freee™**.

freee™ attracted a lot of attention at the event, not least through the presentation given by one of our founders, Professor Håkan Engqvist, on how we use bioceramics in our technology. It brought a wide range of industry stakeholders to our stand, and recently an article was published in Tobacco Reporter about **freee™** and Amplicon's technologies. You will find the YouTube video and the article under News on our website.

freee™ is now being developed with two different flavours, Mintum and Citrum, and the positive response we experienced at GFN confirms that we offer a better experience and effect through a significantly longer release of both nicotine and flavour compared to the small, dry products currently on the market.


There is, therefore, great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches for existing and new markets.

Within **Empli03**, our drug candidate for chronic pain, test batches have been manufactured for use in the PK clinical study. We have completed the required detailed documentation, and the application is now submitted to the UK authorities MHRA and REC handling our application.

We expect to present initial results from the PK study later in the autumn. The results will be used, among other things, as a basis for regulatory consultation with the FDA and business contacts regarding both **Empli03** and the Emplior platform.



There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches”



During the quarter, we started a development project together with Uppsala University. It includes advanced material science characterisation of drug formulations developed by Empliculture and collaboration to design new platforms for formulating biological drugs, biologics. We see great potential in using our bioceramic platforms in the field of biological drugs, resulting in increased patient benefit and more effective treatment.

During the quarter, we also received advance notice of a patent approval in Australia for the Emplihale platform for drug inhalation, further strengthening our project portfolio and upcoming projects. We believe our IP protection is strong and will position us well in discussions with potential licensees and other partners.

In connection with the listing on Nasdaq First North last summer, the company raised MSEK 40 in an oversubscribed unit issue to take **Empli03** through a clinical study and to develop Amplicon and the organisation. During the second quarter, we completed the remaining warrant part of the unit. It was carried out in a difficult market environment and the company raised MSEK 12.3 before issue costs.

At the time of writing, we are in the second half of the year, with significant and exciting milestones in both our main projects. We look forward to returning with news and positive results for **Amp01** and **Empli03**.


Torbjörn W. Larsson
CEO

Emplicure


Emplicure is an innovative company that combines pharmaceutical development and materials science. We develop products and new areas of use by combining active and approved substances with our patented bioceramic platforms. The fact that the substances are already approved means shorter development time, more efficient projects with reduced risk and time to registration will be significantly shorter. Our vision, "Introducing a new generation of products for a better tomorrow", is to create a better future for people by introducing new products with better accuracy when it comes to effect, duration and precision in dose delivery.

We have three different bioceramic platforms to administer drugs on; Emplior for the development of tablets, capsules and medicines for oral uptake, Empliderm for the development of transdermal dosage of medicines e.g., plasters, Emplihale for the development of inhalation of active substances. Combining different substances with bioceramics offers endless possibilities to create products with tailored properties. Our first product candidate is for chronic pain, Empli03 and it will enter the clinical documentation phase at the beginning of next year, 2022. This will be the first time we evaluate the technology platform in clinic.


Empli03 is a pain medicine in the form of an oral, buccal tablet, with properties that counteract the abuse of the product. The product is being developed in the Emplior platform.



Oral administration - Emplior



Administration genom inhalation - Emplihale



Transdermal administration - Empliderm

Amplicon

Our wholly owned subsidiary Amplicon develops new and innovative products for the consumer market. The products will mainly be based on the same bioceramic platforms that Emplicure uses, which enables completely new solutions. Lessons from ongoing projects opens for new generations of consumer products with strong benefits for the consumer. Amplicon will during 2022 prioritise products targeted towards the large and fast-growing non-tobacco nicotine.

For **Amp01**, our consumer project with non-tobacco nicotine for oral use, there are ongoing discussions in different phases with potential licensees and partners. In parallel, Amplicon is developing Amp01 towards a ready product according to a defined product profile. The development and profiling is conducted both inhouse and with external experts. The work with the development of a launch ready product creates a higher commercial value and provides a clearer profile for a potential partner to expect. It is fundamental to constantly move forward and upwards in the value chain. Amp01 is an oral tobacco-free nicotine product in the form of dry, white nicotine pouches for consumers.



Financial information

Net sales and result

The Group has no net sales during the second quarter (KSEK 76 in the same period last year). The operating loss for the second quarter amounted to KSEK -8,674 (KSEK -6,519), while the result during January-June amounted to KSEK -16,001 (KSEK -7,498). The R&D operations, including preparation of the Empli03 clinical trial and the product development of Amp01, have continued to develop according to plan, which explains the higher costs. One more person was employed in Q2 to continue pushing the product development within Amplicon.

Cashflow and investments

Cash flow from operating activities for the second quarter amounted to KSEK -7,812 (KSEK -17,428), including a change in the working capital of KSEK +802 (KSEK -9,527). For the January-June period, the corresponding cash flow amounted to KSEK -13,138 (KSEK -19,714).

Cash flow from investment activities in Q2 amounted to KSEK 0 (KSEK -42). The corresponding number for January-June was KSEK -234 (KSEK -42) and is primarily related to purchase of tangible assets. The Group has no activated costs linked to intangible assets.

Cash flow from financing activities amounted to KSEK +11,650 (KSEK +11,300) in the second quarter, explained by the funds generated by the TO1 in May and the new issue in conjunction with the listing on Nasdaq First North Growth Market in June 2021.

Cash position

The Group's cash and cash equivalents amounted by 30 June 2022 to KSEK 20,338 (KSEK 6,564), compared to KSEK 22,059 by 31 December 2021.

By the subscription of shares in the TO1 in June 2022, the company received a net MSEK 11.6, and it is the opinion of the Board that the Group thereby has sufficient financing to run the operation during 2022 according to plan.

The Group's business model implicates to out license and/or enter partnerships around the Group's products, where milestone payments and royalty payments based on future product sales can make up revenues for the Group.

Warrants

The company has active option programs for key employees and the Board of Directors. You will find a summary under Note 1.

Risks

Management and the Board continuously evaluate risks and uncertainties related to the business. Please refer to the Company's Annual Reports for an account of the risks associated with the company's operations. You will find these on the company's website, www.emplicure.com, under the investor relations/financial reports tab.

Significant events

Events during the reporting period

- In April, the company was informed that a patent is set to be granted in Australia for inhalation of pharmaceuticals. The patent is expected to be granted within the next months, then into 2038.
- In April, Emplicure signed a development agreement with Uppsala university regarding biological medicines.
- At the company's AGM, Gunilla Ekström, Håkan Engqvist, Johan Wieslander and Ingemar Kihlström were re-elected. Gisela Sitbon was elected new board member, while Thomas Lundquist rejected re-election. Gisela Sitbon was later elected new chair of the board.
- In May the company announced the outcome of the TO1, where the company received MSEK 12.3 before transaction costs.
- In June, subsidiary Amplicon announced that it had filed at the European Union Intellectual Property Office (EUIPO) for a trademark registration for its leading product
- In June, subsidiary Amplicon announced that it successfully showcased its products at Global Forum on Nicotine in Warsaw during 16-18 June.

Events after the reporting period

No significant events after the reporting period.

The share

Listing

The Emplicure share was listed at Nasdaq First North Growth Market on June 24, 2021. The instrument name is EMPLI and the ISIN-code is SE0015812391. One (1) share represents one (1) vote.

Number of shares

The number of shares amounted to 26,460,512 at the end of the period (20,558,000 LY). In June 2022, 5,902,512 new shares were subscribed in the second step of the unit issue in conjunction with the listing in June 2021. The average number of shares in the second quarter amounted to 23,217,374, while corresponding number for January-June was 21,887,687, and 15,916,242 for the full year 2021.

Shareholders

The total number of shareholders amounted to approx. 560 by the end of June 2022. The three founders, Thomas Lundqvist, Susanne Bredenberg and Håkan Engqvist (via Aduro Material AB) together control 33.3% of the shares. The ten largest shareholders together own 65.8% of the shares.

Shareholders as of June 30, 2022	Number of shares	Share
Tomas Lundqvist	4,617,324	17.4%
Susanne Bredenberg	2,102,000	7.9%
Aduro Material AB*	2,084,710	7.9%
Monesi Förvaltning	1,955,216	7.4%
Johan Wieslander AB	1,620,000	6.1%
Peyman Pournouri	1,607,049	6.1%
Hadi Ghafori	937,587	3.5%
Avanza Pensionsförs	874,272	3.3%
Deseven Capital	831,324	3.1%
Olle Olsson Holding	783,000	3.0%
10 Largest shareholders, total	17,412,482	65.8%
Other shareholders	9,048,030	34.2%
Total	26,460,512	100.0%

* Aduro Material AB is controlled by Håkan Engqvist

Consolidated income statement

Amounts in KSEK	Apr-Jun		Jan-Jun		Jan-Dec
	2022	2021	2021	2021	2021
Operating income					
Net sales	-	76	-	76	80
Other operating income	4	-40	33	-40	6
Total income	4	37	33	37	86
Operating expenses					
R&D costs	-3,705	-664	-6,210	-732	-406
Other external expenses	-3,056	-3,097	-5,498	-3,442	-10,685
Personnel costs	-1,890	-2,791	-4,183	-3,343	-5,633
Depreciation and impairments on fixed assets	-17	-1	-33	-1	-12
Other operating expenses	-11	-2	-109	-17	-23
Total operating expenses	-8,679	-6,556	-16,034	-7,535	-16,760
Operating loss (EBIT)	-8,674	-6,519	-16,001	-7,498	-16,673
Financial items					
Financial income	-	-	-	-	21
Financial expenses	-0	-1,385	-0	-1,763	-1,763
Net financial items	-0	-1,385	-0	-1,763	-1,742
Profit/loss after financial items	-8,674	-7,904	-16,001	-9,261	-18,415
Profit/loss before tax	-8,674	-7,904	-16,001	-9,261	-18,415
Tax	-	-	-	-	-
Profit/Loss for the period	-8,674	-7,904	-16,001	-9,261	-18,415
Average number of shares	23,217,374	11,590,967	21,887,687	11,274,484	15,916,242
Earnings per share before and after dilution	-0.37	-0.68	-0.69	-0.80	-0.90

Consolidated balance sheet

Amounts in KSEK	30 Jun		31 Dec
	2022	2021	2021
ASSETS			
FIXED ASSETS			
Tangible fixed assets	298	41	97
Total fixed assets	298	41	97
CURRENT ASSETS			
Other receivables	1,429	27,410	2,275
Prepayments and accrued income	580	156	279
Cash and cash equivalents	20,337	6,525	22,059
Total current assets	22,347	34,091	24,613
TOTAL ASSETS	22,645	34,131	24,710
EQUITY AND LIABILITIES			
EQUITY			
Share capital	1,323	1,028	1,028
Other paid-in capital	54,878	36,775	43,523
Other equity including the result for the period	-38,928	-7,161	-23,051
Total equity	17,273	30,643	21,500
CURRENT LIABILITIES			
Accounts payable	2,409	1,077	1,305
Deferred taxes	-	-	58
Other current liabilities	691	180	223
Accruals and deferred income	2,273	2,272	1,624
Total current liabilities	5,373	1,256	1,585
TOTAL EQUITY AND LIABILITIES	22,645	31,899	23,085

Change in equity for the group

Amounts in KSEK	Share capital	Other paid-in capital	Other equity	Total equity
Amount at the beginning of the period (1 Jan 2022)	1,028	43,523	-23,051	21,500
Employee stock option	-	-	124	124
Profit for the period	-	-	-16,001	-16,001
Amount at the end of the period (30 Jun 2022)	1,323	54,878	-38,928	17,273
Amount at the beginning of the period (1 Jan 2021)	110	2,312	34,464	36,885
Bonus issue	438	-	-	438
New share issue	480	-	-	480
Profit for the period	-	-	-7,161	-7,161
Amount at the end of the period (30 Jun 2021)	1,028	2,312	27,303	30,643

Consolidated cash flow analysis

Amounts in KSEK	Apr-Jun		Jan-Jun		Jan-Dec
	2022	2021	2022	2021	2021
OPERATING ACTIVITIES					
Operating profit	-8,674	-6,519	-16,000	-7,454	-16,673
Adjustments for items not included in cash flow	79	21	156	21	92
Financial net	-0	-1,385	-0	-1,762	-1,742
Tax paid	-18	-18	-36	-45	41
Cash flow from operating activities before changes in working capital	-8,613	-7,900	-15,880	-9,240	-18,283
Increase/decrease other current receivables	-448	-274	544	-1,049	-2,156
Increase/decrease other current liabilities	1,250	-9,253	2,199	-9,425	1,923
Cash flow from operating activities	-7,812	-17,428	-13,138	-19,714	-18,516
INVESTING ACTIVITIES					
Acquisition of material assets	-	-42	-234	-42	-109
Cash flow from investing activities	-	-42	-234	-42	-109
FINANCING ACTIVITIES					
New share issue	12,336	11,300	12,336	11,300	39,840
Paid warrants	-	-	-	-	162
Convertible bonds	-	-	-	11,750	-
Cash flow from financing activities	11,650	11,300	11,650	23,050	37,414
Cash flow for the period	3,838	-6,169	-1,722	3,294	18,789
Cash and cash equiv. at the beginning of the period	16,499	12,734	22,059	3,270	3,270
Cash and cash equiv. at the end of the period	20,338	6,564	20,338	6,564	22,059

Income statement, parent company

Emplicure AB (parent company)	Apr-Jun		Jan-Jun		Jan-Dec
	2022	2021	2022	2021	2021
Amounts in KSEK					
Operating income					
Net sales	498	76	901	76	486
Other operating income	4	5	33	5	6
Total income	502	82	934	82	492
Operating expenses					
R&D costs	-3,323	-532	-5,670	-600	-406
Other external expenses	-2,426	-3,069	-4,547	-3,349	-9,885
Personnel costs	-1,834	-2,836	-4,061	-3,343	-5,437
Depreciation and impairments on fixed assets	-17	-1	-33	-1	-12
Other operating expenses	-11	-2	-107	-17	-23
Operating loss (EBIT)	-7,109	-6,358	-13,484	-7,228	-15,272
Financial items					
Result from participations in subsidiary	-1,627	-	-2,037	-	-910
Financial income	-	-	-	-	21
Financial expenses	-	-1,385	-	-1,763	-1,763
Net financial items	-1,627	-1,385	-2,037	-1,763	-2,652
Profit/loss after financial items	-8,736	-7,743	-15,521	-8,991	-17,924
Provided group contributions	-	-	-	-	-1,390
Profit/loss before tax	-8,736	-7,743	-15,521	-8,991	-19,314
Tax	-	-	-	-	-
Profit/Loss for the period	-8,736	-7,743	-15,521	-8,991	-19,314

Balance sheet, parent company

Emplicure AB (parent company) Amounts in KSEK	30 Jun		31 Dec
	2022	2021	2021
FIXED ASSETS			
Tangible fixed assets	298	41	97
Shares in affiliated undertakings	25	305	25
Total fixed assets	323	344	122
CURRENT ASSETS			
Other receivables	561	27,324	1,966
Prepayments and accrued income	565	141	251
Cash and cash equivalents	19,824	6,525	22,044
Total current assets	20,951	33,991	24,260
TOTAL ASSETS	21,274	34,335	24,382
EQUITY			
Restricted capital			
Share capital	1,323	1,028	1,028
Total restricted capital	1,323	1,027	1,028
Shareholders surplus			
Share premium account	54,636	36,775	43,282
Surplus brought forward	-23,584	2,056	-4,394
Other equity including profit for the period	-15,521	-8,991	-19,314
Total shareholders surplus	15,531	29,840	19,574
Total equity	16,854	30,867	20,602
CURRENT LIABILITIES			
Accounts payable	1,817	1,021	1,253
Amounts owed to affiliated undertakings	-	-	883
Deferred taxes	-	-	58
Other current liabilities	514	177	223
Accruals and deferred income	2,090	2,272	1,363
Total current liabilities	4,420	3,470	3,780
TOTAL EQUITY AND LIABILITIES	21,274	34,337	24,382

Cash flow analysis, parent company

Emplicure AB (parent company) Amounts in KSEK	Apr-Jun		Jan-Jun		Jan-Dec
	2022	2021	2022	2021	2021
OPERATING ACTIVITIES					
Operating profit	-7,109	-6,358	-13,484	-7,228	-15,272
Adjustments for items not included in cash flow	79	22	156	22	92
Net financial items	-	-1,385	-	-1,762	-1,742
Tax paid	-18	-18	-36	-45	41
Cash flow from operating activities before changes in working capital	-7,048	-7,739	-13,364	-9,013	-16,881
Increase/decrease other current receivables	986	-191	1,652	-950	-1,818
Increase/decrease other current liabilities	-582	-9,232	113	-9,485	2,493
Cash flow from operating activities	-6,644	-17,162	-11,599	-19,448	-16,206
INVESTING ACTIVITIES					
Acquisition of tangible assets	-	-42	-234	-42	-109
Provided group contributions	-1,627	-280	-2,037	-280	-910
Acquisition of affiliated companies	-	-	-	-	-
Cash flow from investing activities	-1,627	-322	-2,271	-322	-1,019
FINANCING ACTIVITIES					
New share issue, gross	12,336	11,300	12,336	11,300	37,252
Costs related to the new share issue	-686	-	-686	-	-
Received shareholders contribution	-	-	-	-	-1,390
Paid warrants	-	-	-	-	162
Convertible bonds	-	-	-	11,750	-
Cash flow from financing activities	11,650	11,300	11,650	23,050	36,024
Cash flow for the period	3,379	-6,184	-2,219	3,280	18,799
Cash and cash equiv. at the beginning of the period	16,446	12,709	22,044	3,245	3,245
Cash and cash equiv. at the end of the period	19,824	6,525	19,824	6,525	22,044

Notes

ACCOUNTING PRINCIPLES

The interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general advice BFNAR 2012:1 Annual Report and consolidated accounts (K3).

The same accounting principles and calculation methods have been used in the interim report as in the most recent annual report.

REVIEW BY AUDITOR

This report has not been reviewed by the Company's auditor.

TRANSACTIONS WITH RELATED PARTIES

Companies related to the CFO and several members of the board have during the period had agreements on consulting services with the company. Transactions with related parties are on market terms.

CONSOLIDATED STATEMENTS

As of the fourth quarter 2021, since the affiliated company Amplicon has started its business, consolidated accounts are prepared and reported.

INFORMATION ON CERTAIN ITEMS

Note 1 Disclosure of share capital and warrants

	<u>No. of shares</u>	<u>Quota per share</u>
Number/value at the beginning of the period	20,558,000	0.05
New shares issue by the use of warrants	5,912,512	0.05
Number/value at the end of the period	26,460,512	0.05

Program	Number of warrants acquired at the beginning of the period	Number of warrants acquired during the period	Number of warrants exercised during the period	Number of warrants at the end of the period	Terms	Subscription price (SEK)
2019/2022	325 000	0	0	325 000	One warrant entitles to subscribe for 1 share	15,00
Subscription period 1 July 2022 until 31 December 2022.						
2021/2024	363 249	0	0	363 249	One warrant entitles to subscribe for 1 share	9,58
Subscription period 6 April 2024 until 6 July 2024						
TO1 (issued as a part of the units issued in connection with the company's listing on Nasdaq First North)	9 600 000	0	5 902 512	0	One warrant entitles to subscribe for 1 share	A total of 5,902,512, of potentially 9,600,000, shares were subscribed at SEK 2.09.
Subscription period 29 April 2022 until 13 May 2022						

Program	Number of warrants acquired at the beginning of the period	Number of warrants acquired during the period	Number of warrants exercised during the period	Number of warrants at the end of the period	Terms	Subscription price (SEK)
2021/2024 (non-qualified)	108 975	0	0	108 975	Each employee stock option entitles the participant to either (i) acquire a new share in the company at a subscription price of SEK 9.58, or (ii) receive a cash compensation corresponding to the difference between the market value of the company's share at the time of exercise and the subscription price of SEK 9.58	

The employee share options may be exercised no earlier than 3 years and no later than 3 years and 3 months after the participant has signed the program

Warrants of series 2021/2025* have been issued to secure the company's delivery of shares. These are not reported in the table above regarding warrants.

2021/2025 (qualified)	503 790*	0	0	503 790	Each employee share option gives the right to acquire on new share in the company	9,58
-----------------------	----------	---	---	---------	---	------

The employee share options may be exercised no earlier than 3 years and no later than 3 years and 3 months after the participant has signed the program

Warrants of series 2021/2025* have been issued to secure the company's delivery of shares. These are not reported in the table above regarding warrants.

*The remaining 101.624 qualified employee share options expired 31 December 2021, hence the total program amounted to 503.790 employee share options.

2022/2025 (qualified)	0**	0	0	0	Each employee share option gives the right to acquire on new share in the company	8,00
-----------------------	-----	---	---	---	---	------

The employee share options may be exercised no earlier than 3 years and no later than 3 years and 3 months after the participant has signed the program

Warrants of series 2022/2025* have been issued to secure the company's delivery of shares. These are not reported in the table above regarding warrants.

**At the AGM in April 2022 it was decided to issue 614,740 qualified employee share options to certain board members in the company and in Amplicon. Non of these had been acquired by 2022-06-30

2022/2025 (qualified)	0***	0	0	0	Each employee share option gives the right to acquire on new share in the company	8,00
-----------------------	------	---	---	---	---	------

The employee share options may be exercised no earlier than 3 years and no later than 3 years and 3 months after the participant

Warrants of series 2022/2025* have been issued to secure the company's delivery of shares. These are not reported in the table above regarding warrants.

***At the AGM in April 2022 it was decided to issue 411,160 qualified employee share options to the management and employees in Emplicure. Non of these had been acquired by 2022-06-30

Note 2 Definition of Key ratios

Earnings per share:	Net results divided by the average number of shares
Equity ratio:	Adjusted equity as a percentage of total assets
Net cash flow:	Change in cash and cash equivalents excluding FX effects

Attestation

The Board of Directors and the President & CEO hereby affirm that the Year End Report constitutes a faithful representation of the company's and the Group's operations, position and profit/loss, and that it describes the significant risks and uncertainty factors faced by the company and the companies that make up the Group.

Uppsala 18 August, 2022

Gisela Sitbon
Chairman of the board

Torbjörn Walker Larsson
CEO

Gunilla Ekström
Board member

Håkan Engqvist
Board member

Ingemar Kihlström
Board member

Johan Wieslander
Board member

Additional information

Contact

Torbjörn Walker Larsson, CEO
twl@emplicure.com

Erik Magnusson, CFO
erik.magnusson@emplicure.com

Certified adviser

Mangold Fondkommission AB
ca@mangold.se
08-503 01 550

Financial calendar 2022/23

Q3 2022
Q4 2022
AGM 2022

17 Nov
23 Feb '23
11 May '23